The Relationship Between Plexin C1 Overexpression and Survival in Hepatocellular Carcinoma: a Turkish Oncology Group (TOG) Study
Authors:
- 3 March 2021
- journal article
- research article
- Published by Springer Nature in Journal of Gastrointestinal Cancer
- Vol. 53 (2) , 356-362
Abstract
Purpose Plexin C1 is a transmembrane receptor and plexin C1 overexpression might have role in carcinogenesis. Hepatocellular carcinoma (HCC) has poor prognosis because of its aggressive behavior and limited treatment options, especially in advanced stage. We recently documented that Plexin C1 was overexpressed in HCC. We aimed to evaluate the prognostic significance of Plexin C1 overexpression in HCC in the present study. Methods Plexin C1 overexpression was evaluated immunohistochemically on paraffin-embedded blocks of the HCC patients. Plexin C1 immunohistochemical staining was scored. Plexin C1 overexpression staining intensity and prevalence were used for plexin scale staining evaluation and plexin scores were estimated according this staining scale. Plexin C1 score and its association with survival and clinicopathological features was assessed. Results Sixty-seven HCC patients with adequate tissue for pathological evaluation were included. Median age was 63 years with male predominance (male to female ratio was 4.75 (n 57/12). Well-differentiated HCC (53.7%) patients had higher plexin C1 overexpression (p < 0.05). Median OS was 22.1 months. Patients with lower plexin C1 score (< 12) had shorter OS (17.5 vs 30.1 months, p = 0.036). Neutrophil count, GGT, and PNR (platelet/neutrophil ratio) had prognostic significance (p = 0.047, p = 0.018, and p = 0.045). Conclusion Plexin C1 overexpression is inversely correlated with grade in HCC. The patients with lower rate of Plexin C1 overexpression have worse survival outcome. It might be a prognostic factor in HCC.Keywords
This publication has 13 references indexed in Scilit:
- Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trialThe Lancet, 2018
- Emerging role of plexins signaling in glioma progression and therapyCancer Letters, 2018
- Personalized therapy for hepatocellular carcinoma: Where are we now?Cancer Treatment Reviews, 2016
- Semaphorins in Angiogenesis and Tumor ProgressionCold Spring Harbor Perspectives in Medicine, 2011
- Plexin A-Semaphorin-1a Reverse Signaling Regulates Photoreceptor Axon Guidance inDrosophilaJournal of Neuroscience, 2010
- Plexin B1 Suppresses c-Met in Melanoma: A Role for Plexin B1 as a Tumor-Suppressor Protein through Regulation of c-MetJournal of Investigative Dermatology, 2010
- Plexin C1, A Receptor for Semaphorin 7A, Inactivates Cofilin and Is a Potential Tumor Suppressor for Melanoma ProgressionJournal of Investigative Dermatology, 2009
- Loss of Plexin B1 is highly prognostic in low proliferating ER positive breast cancers – Results of a large scale microarray analysisEuropean Journal of Cancer, 2008
- Plexin-B1 mutations in prostate cancerProceedings of the National Academy of Sciences, 2007
- A Poxvirus-Encoded Semaphorin Induces Cytokine Production from Monocytes and Binds to a Novel Cellular Semaphorin Receptor, VESPRImmunity, 1998